Method of using a biosensor

Information

  • Patent Grant
  • 9410917
  • Patent Number
    9,410,917
  • Date Filed
    Friday, February 28, 2014
    10 years ago
  • Date Issued
    Tuesday, August 9, 2016
    8 years ago
Abstract
A biosensor (102) for determining the presence or amount of a substance in a sample and methods of use of the biosensor (102) are provided. The biosensor (102) for receiving a user sample to be analyzed includes a mixture for electrochemical reaction with an analyte. The mixture includes an enzyme, a mediator and an oxidizable species as an internal reference.
Description
FIELD OF THE INVENTION

The present invention generally relates to a biosensor, and, more particularly, to a new and improved biosensor, including an oxidizable species as an internal reference and methods of use of the biosensor, for determining the presence or amount of a substance in a sample.


DESCRIPTION OF THE PRIOR ART

The quantitative determination of analytes in body fluids is of great importance in the diagnoses and maintenance of certain physiological abnormalities. For example lactate, cholesterol and bilirubin should be monitored in certain individuals. In particular, the determination of glucose in body fluids is of great importance to diabetic individuals who must frequently check the level of glucose in their body fluids as a means of regulating the glucose intake in their diets. While the remainder of the disclosure herein will be directed towards the determination of glucose, it is to be understood that the new and improved sensor element and method of use of this invention can be used for the determination of other analytes upon selection of the appropriate enzyme.


Methods for determining analyte concentration in fluids can be based on the electrochemical reaction between the analyte and an enzyme specific to the analyte and a mediator which maintains the enzyme in its initial oxidation state. Suitable redox enzymes include oxidases, dehydrogenases, catalase and peroxidase. For example, in the case where glucose is the analyte, the reaction with glucose oxidase and oxygen is represented by equation:




embedded image


In the initial step of the reaction represented by equation (A), glucose present in the test sample converts the enzyme (Eox), such as the oxidized flavin adenine dinucleotide (FAD) center of the enzyme into its reduced form (Ered), for example, (FADH2). Because these redox centers are essentially electrically insulated within the enzyme molecule, direct electron transfer to the surface of a conventional electrode does not occur to any measurable degree in the absence of an unacceptably high cell voltage. An improvement to this system involves the use of a nonphysiological redox coupling between the electrode and the enzyme to shuttle electrons between the (FADH2) and the electrode. This is represented by the following scheme in which the redox coupler, typically referred to as a mediator, is represented by M:

Glucose+GO(FAD)→gluconolactone+GO(FADH2)
GO(FADH2)+2Mox→GO(FAD)+2Mred+2H+
2Mred→2Mox+2e(at the electrode)


In the scheme, GO(FAD) represents the oxidized form of glucose oxidase and GO(FAD H2) indicates its reduced form. The mediating species Mox/Mred shuttles electrons from the reduced enzyme to the electrode thereby oxidizing the enzyme causing its regeneration in situ.


U.S. Pat. Nos. 5,620,579 and 5,653,863 issued to Genshaw et al., and assigned to the present assignee, disclose apparatus and method for determining the concentration of an analyte in a fluid test sample by applying the fluid test sample to the surface of a working electrode, which is electrochemically connected to a counter electrode, and which surface bears a composition comprising an enzyme specific for the analyte. A mediator is reduced in response to a reaction between the analyte and the enzyme. An oxidizing potential is applied between the electrodes to return at least a portion of the mediator back to its oxidized form before determining the concentration of the analyte to thereby increase the accuracy of the analyte determination. Following this initially applied potential, the circuit is switched to an open circuit or to a potential that substantially reduces the current to minimize the rate of electrochemical potential at the working electrode. A second potential is applied between the electrodes and the current generated in the fluid test sample is measured to determine analyte concentration. Optionally, the accuracy of the analyte determination is further enhanced algorithmically.


SUMMARY OF THE INVENTION

Important aspects of the present invention are to provide a new and improved biosensor for determining the presence or amount of a substance in a sample including an oxidizable species as an internal reference and method of use of the biosensor.


In brief, a biosensor for determining the presence or amount of a substance in a sample and methods of use of the biosensor are provided. The biosensor for receiving a user sample to be analyzed includes a mixture for electrochemical reaction with an analyte. The mixture includes an enzyme, a mediator and an oxidizable species as an internal reference.


The internal reference is defined as the oxidizable species which in one embodiment can be further defined as the reduced form of a reversible redox couple that has an equal or higher redox potential than that of the mediator. The internal reference acts to increase the response current additively for operation potentials that oxidize both species and in the case where glucose is the analyte, a total response current is represented by:

Itotal=Iint-ref+Iglucose
Iint-ref∝(internal reference) and Iglucose∝(glucose);

Where Iint-ref is the portion of the total response current due to the internal reference, while Iglucose is due to the oxidation of mediator proportional to the glucose concentration.


In accordance with features of the invention, the internal reference can be either the same mediator species or an oxidizable species with a higher redox potential than the mediator. Thus for biosensors with a low operation potential oxidizing only the mediator, the current Iint-ref will be zero. However, for biosensors with a higher operation potential that oxidizes both species, the total response current will be the sum of the portion due to internal reference and that due to glucose. Since the internal reference concentration is fixed, the calibration slope of the sensor will only depend on the sensor response for glucose while the intercept will depend on the added amount of the internal reference. In another words, the internal reference will only offset the intercept and will not change the calibration slope. Thus, the concept of internal reference provides new and different ways to make glucose biosensors.





BRIEF DESCRIPTION OF THE DRAWINGS

The present invention together with the above and other objects and advantages may best be understood from the following detailed description of the preferred embodiments of the invention illustrated in the drawings, wherein:



FIG. 1A is a block diagram representation of biosensor meter including a biosensor having an internal reference in accordance with the present invention;



FIGS. 1B, 1C, and 1D are diagrams respectively illustrating operational methods for use with the biosensor of FIG. 1 of the invention;



FIGS. 2A, 2B, and 2C are charts showing three cyclic voltammograms of MLB based glucose biosensors with ferrocyanide as the internal reference the biosensor of FIG. 1 of the invention in whole blood samples of 0 mg/dL glucose;



FIG. 3 is a chart illustrating a linear response of the biosensor of FIG. 1 of the invention at different voltage operating potentials;



FIG. 4 is a chart illustrating effect of the added internal reference to the overall voltammetric current using biosensors of FIG. 1 of the invention with 10% printed ferricyanide as the counter electrode;



FIGS. 5A and 5B are charts illustrating linear response and increased intercept with increasing internal reference of MLB based biosensors of FIG. 1 of the invention with Ag/AgCl as the counter electrode;



FIGS. 6A and 6B are charts illustrating linear response and increased intercept with increasing internal reference of MLB based biosensors of FIG. 1 of the invention with 10% ferricyanide as the counter electrode;



FIG. 7 is a chart illustrating linear relationship of the calibration intercept with increasing internal reference of DEX biosensors of FIG. 1 of the invention with 10% ferricyanide as the counter electrode; and



FIGS. 8A and 8B are charts illustrating the ratio of signal to reference results from flow-injection-analysis (FIA) of the residual ferrocyanide from a control reagent ink and the reagent ink with 0.1% ferrocyanide added to the reagent mixture of 20% ferricyanide of a biosensor of FIG. 1 of the invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention relates to an electrochemical biosensor for determining the presence or amount of a substance in a sample. The biosensor includes sensor strips containing a working electrode and a counter electrode, each of which is at least partially covered with, for example, a separate reagent layer. The reagent layer on the working electrode includes, for example, an enzyme that interacts with an analyte through an oxidation-reduction reaction and also includes a mediator that is the oxidized form of a redox couple. The biosensor of the invention includes an internal reference or a reduced form of the mediator in the reagent layer on the working electrode. The internal reference is defined as an oxidizable species which in one embodiment can be further defined as a reduced form of a reversible redox couple that has an equal or higher redox potential than that of the mediator. A fixed quantative amount of the internal reference is provided in the reagent layer. The biosensors of the invention including the internal reference or added amount of the reduced form of mediator provide for improvements in that the internal reference acts to anchor the calibration intercept by nature of thermodynamics while maintaining the calibration slope.


Many compounds are useful as mediators due to their ability to accept electrons from the reduced enzyme and transfer them to the electrode. A necessary attribute of a mediator is the ability to remain in the oxidized state under the conditions present on the electrode surface prior to the use of the sensor. Among the more venerable mediators are the oxidized form of organometallic compounds, organic molecules, transition metal coordination complexes. A specific example of mediator is the potassium hexacyanoferrate (III), also known as ferricyanide.


As used in the following specification and claims, the term biosensor means an electrochemical sensor strip or sensor element of an analytical device or an instrument that responds selectively to analytes in an appropriate sample and converts their concentration into an electrical signal. The biosensor generates an electrical signal directly, facilitating a simple instrument design. Also, a biosensor offers the advantage of low material cost since a thin layer of chemicals is deposited on the electrodes and little material is wasted.


The term “sample” is defined as a composition containing an unknown amount of the analyte of interest. Typically, a sample for electrochemical analysis is in liquid form, and preferably the sample is an aqueous mixture. A sample may be a biological sample, such as blood, urine or saliva. A sample may be a derivative of a biological sample, such as an extract, a dilution, a filtrate, or a reconstituted precipitate.


The term “analyte” is defined as a substance in a sample, the presence or amount of which is to be determined. An analyte interacts with the oxidoreductase enzyme present during the analysis, and can be a substrate for the oxidoreductase, a coenzyme, or another substance that affects the interaction between the oxidoreductase and its substrate.


The term “oxidoreductase” is defined as any enzyme that facilitates the oxidation or reduction of a substrate. The term oxidoreductase includes “oxidases,” which facilitate oxidation reactions in which molecular oxygen is the electron acceptor; “reductases,” which facilitate reduction reactions in which the analyte is reduced and molecular oxygen is not the analyte; and “dehydrogenases,” which facilitate oxidation reactions in which molecular oxygen is not the electron acceptor. See, for example, Oxford Dictionary of Biochemistry and Molecular Biology, Revised Edition, A. D. Smith, Ed., New York: Oxford University Press (1997) pp. 161, 476, 477, and 560.


The term “oxidation-reduction” reaction is defined as a chemical reaction between two species involving the transfer of at least one electron from one species to the other species. This type of reaction is also referred to as a “redox reaction.” The oxidation portion of the reaction involves the loss of at least one electron by one of the species, and the reduction portion involves the addition of at least one electron to the other species. The ionic charge of a species that is oxidized is made more positive by an amount equal to the number of electrons transferred. Likewise, the ionic charge of a species that is reduced is made less positive by an amount equal to the number of electrons transferred.


The term “oxidation number” is defined as the formal ionic charge of a chemical species, such as an atom. A higher oxidation number, such as (III), is more positive, and a lower oxidation number, such as (II), is less positive. A neutral species has an ionic charge of zero. Oxidation of a species results in an increase in the oxidation number of that species, and reduction of a species results in a decrease in the oxidation number of that species.


The term “redox pair” is defined as two species of a chemical substance having different oxidation numbers. Reduction of the species having the higher oxidation number produces the species having the lower oxidation number. Alternatively, oxidation of the species having the lower oxidation number produces the species having the higher oxidation number.


The term “oxidizable species” is defined as the species of a redox pair having the lower oxidation number, and which is thus capable of being oxidized into the species having the higher oxidation number. Likewise, the term “reducible species” is defined as the species of a redox pair having the higher oxidation number, and which is thus capable of being reduced into the species having the lower oxidation number.


The term “organotransition metal complex,” also referred to as “OTM complex,” is defined as a complex where a transition metal is bonded to at least one carbon atom through a sigma bond (formal charge of −1 on the carbon atom sigma bonded to the transition metal) or a pi bond (formal charge of 0 on the carbon atoms pi bonded to the transition metal). For example, ferrocene is an OTM complex with two cyclopentadienyl (Cp) rings, each bonded through its five carbon atoms to an iron center by two pi bonds and one sigma bond. Another example of an OTM complex is ferricyanide (III) and its reduced ferrocyanide (II) counterpart, where six cyano ligands (formal charge of −1 on each of the 6 ligands) are sigma bonded to an iron center through the carbon atoms of the cyano groups.


The term “coordination complex” is defined as a complex having well-defined coordination geometry, such as octahedral or square planar geometry. Unlike OTM complexes, which are defined by their bonding, coordination complexes are defined by their geometry. Thus, coordination complexes may be OTM complexes (such as the previously mentioned ferricyanide), or complexes where non-metal atoms other than carbon, such as heteroatoms including nitrogen, sulfur, oxygen, and phosphorous, are datively bonded to the transition metal center. For example, ruthenium hexaamine, or hexaaminoruthenate (II)/(III), is a coordination complex having a well-defined octahedral geometry where six NH3 ligands (formal charge of 0 on each of the 6 ligands) are datively bonded to the ruthenium center. Ferricyanide is also an example of the coordination complex that has the octahedral geometry. A more complete discussion of organotransition metal complexes, coordination complexes, and transition metal bonding may be found in Collman et al., Principles and Applications of Organotransition Metal Chemistry (1987) and Miessler & Tarr, Inorganic Chemistry (1991).


The term “mediator” is defined as a substance that can be oxidized or reduced and that can transfer one or more electrons between a first substance and a second substance. A mediator is a reagent in an electrochemical analysis and is not the analyte of interest. In a simplistic system, the mediator undergoes a redox reaction with the oxidoreductase after the oxidoreductase has been reduced or oxidized through its contact with an appropriate substrate. This oxidized or reduced mediator then undergoes the opposite reaction at the electrode and is regenerated to its original oxidation number.


The term “electroactive organic molecule” is defined as an organic molecule that does not contain a metal and that is capable of undergoing an oxidation or reduction reaction. Electroactive organic molecules can behave as redox species and as mediators. Examples of electroactive organic molecules include coenzyme pyrroloquinoline quinone (PQQ), benzoquinones and naphthoquinones, N-oxides, nitroso compounds, hydroxylamines, oxines, flavins, phenazines, phenothiazines, indophenols, and indamines.


The term “electrode” is defined as an electrically conductive substance that remains stationary during an electrochemical analysis. Examples of electrode materials include solid metals, metal pastes, conductive carbon, conductive carbon pastes, and conductive polymers.


Having reference now to the drawings, in FIG. 1 there is illustrated a biosensor meter designated as a whole by the reference character 100 of the preferred embodiment and arranged in accordance with principles of the present invention. Biosensor meter 100 includes a biosensor 102 arranged in accordance with principles of the present invention. Biosensor meter 100 includes microprocessor 104 together with an associated memory 106 for storing program and user data. Digital data from the microprocessor 104 is applied to a digital-to-analog (D/A) converter 108. D/A converter 108 converts the digital data to an analog signal. An amplifier 110 coupled to the D/A converter 108 amplifies the analog signal. The amplified analog signal output of amplifier 110 is applied to the biosensor 102 of the invention. Biosensor 102 is coupled to an amplifier 112. The amplified sensed signal is applied to an analog-to-digital (A/D) converter 114 that converts the amplified, analog sensor signal to a digital signal. The digital signal is applied to the microprocessor 104.


Most of the commercially available disposable biosensors used for monitoring blood glucose require the deposition/printing of a mixture of an enzyme and a mediator with some binding agent. For the application of glucose measurement, the mediator is in the oxidized form of a redox couple. Depending on the redox couple, the mediator can be a very strong oxidant, such as ferricyanide, thereby chemically oxidizing the functional groups after mixing with the enzyme and the binding agent. Subsequently, a small amount of the reduced mediator is formed as impurity in the reagent in the processes of ink mixing, storage and printing. Thus, the end result of mixing and printing the reagent ink is the generation of the reduced form of the redox couple, giving rise to the background current. The formation of this reduced form of the mediator and thus the background current may vary from batch to batch. This process-generated reduced form of the mediator, such as ferrocyanide from ferricyanide, can be oxidized in general to minimize the background signal using the algorithm outlined in the U.S. Pat. Nos. 5,620,579 and 5,653,863, to Genshaw et al., and assigned to the present assignee. However, the process-dependent background signal, which is translated into the calibration intercept, can be spread out in a range of values. At the extremes of these diverged values of intercept, analytical accuracy will be suffered because no reasonable calibration intercept can be assigned to accommodate the diverged intercept.


In accordance with features of the invention, a grade of mediator that contains a certain level of the reduced form of the mediator in the reagent is used for decreasing the effect of the strong oxidant. Thermodynamically, the presence of a small amount of the reduced form of the mediator in the ink mixture of enzyme and mediator decreases the driving force for the conversion from the oxidized to the reduced form. This is advantageously accomplished by adding a small fixed amount of the reduced form of the mediator to the oxidized mediator.


Even though background signal will be generated, the algorithm in the U.S. Pat. Nos. 5,620,579 and 5,653,863 will minimize the effect of background to increase the accuracy of the glucose sensor. The above-identified patents disclose a method that reduces the background bias due to oxidizable impurities in an amperometric sensor used for measuring a specific analyte, such as glucose, in blood. The background current of such a sensor will increase if it is stored over a long period of time or under stress (heat, moisture, etc.) due to the increased presence of reduced mediator or other reduced impurity present in the sensor such as enzyme stabilizers, e.g. glutamate, and surfactants having reducing equivalents. For example, in a ferricyanide based amperometric sensor, the background bias is related to the presence of ferrocyanide (from the reduction of ferricyanide) near the electrode surface. This accumulated ferrocyanide, as opposed to the ferrocyanide produced during use of the sensor (fresh ferrocyanide), is oxidized back to ferricyanide to reduce the background bias it causes and thereby extend the sensor shelf life. To achieve this objective, the method uses an electrochemical approach. The background bias is further reduced when the electrochemical approach is augmented with an algorithmic correction.


The disclosed method involves first applying a positive potential pulse (called the “burn-off” pulse) which precedes the normal potential profile during use of the biosensor. This is typically accomplished by applying a positive potential of from 0.1 to 0.9 volt (preferably 0.3 to 0.7 volt) between the working and reference electrodes of the sensor for a period of from 1 to 15 seconds (preferably 5 to 10 seconds). The burn-off pulse oxidizes the initial ferrocyanide (or other oxidizable impurity), so that the sensor can begin the assay with a clean background. Typically, the background is not perfectly clean since only a portion of the oxidizable impurity is oxidized by the burn-off pulse. This is the case because the chemical layer covers both the working and the counter electrodes. The initial ferrocyanide exists in the chemical layer since it comes from ferricyanide. When sample fluid is applied and the chemical layer re-hydrates, the ferrocyanide near the working electrode is re-oxidized. The rest of the ferrocyanide diffuses into the sample fluid and is mixed with the glucose. That portion of the initial ferrocyanide cannot be re-oxidized without affecting the glucose. The initial ferrocyanide is near the electrode for a very short time (a few seconds) after the fluid test sample is applied. The reason for this is that the chemicals (enzyme and ferricyanide, etc.) are deposited as a thin layer on the working and counter electrodes. The burn-off technique takes advantage of this since a significant amount of the initial ferrocyanide can be burned off without noticeable reduction of the analyte concentration in the fluid test sample most of which does not come into direct contact with the electrode. Experiments have demonstrated that the background bias of a stressed sensor can be reduced by 40% with proper application of the burn-off pulse.


The disclosed method of the U.S. Pat. Nos. 5,620,579 and 5,653,863 advantageously is applied to minimize the effect of background signal to increase the accuracy of the glucose biosensor meter 100 of the preferred embodiment. The subject matter of the above-identified patents is incorporated herein by reference.


In accordance with features of the invention, the added amount of the reduced form of mediator acts to anchor the calibration intercept by nature of thermodynamics while maintaining the calibration slope. In light of the function the reduced form of mediator, for example, ferrocyanide, plays in the glucose sensor, it is referred to as the internal reference.


Examples of electroactive organic molecule mediators are described in U.S. Pat. No. 5,520,786, issued to Bloczynski et al. on May 28, 1996, and assigned to the present assignee. In particular, a disclosed mediator (compound 18 in TABLE 1) comprising 3-phenylimino-3H-phenothiazine referred to herein as MLB-92, has been used to make a glucose biosensor 102 in accordance with features of the invention. The subject matter of the above-identified patent is incorporated herein by reference.


A commercially available biosensor meter and biosensor is manufactured and sold by Bayer Corporation under the trademark Ascensia DEX. The Ascensia DEX biosensor includes generally as pure a form of ferricyanide as possible for the reagent. The Ascensia DEX biosensor has been used to make a glucose biosensor 102 in accordance with features of the invention by adding an adequate amount of ferrocyanide to the pure ferricyanide. Benefits of adding ferrocyanide defining the internal reference of biosensor 102 to the Ascensia DEX reagent ink include an immediate benefit of increasing the intercept without changing slope, anchoring the intercept range, and increasing long-term stability of biosensor during storage.


In accordance with features of the invention, the MLB-92 mediator having a lower redox potential was used to make a glucose biosensor 102 with special properties. With the addition of adequate amounts of the internal reference, ferrocyanide, the new biosensor system can be made to work with two operation potentials: (1) at 400 mV where both the new mediator and the internal reference are oxidized, and (2) at 100 mV where only the new mediator can be oxidized. The significance of this approach is two-fold. First, the glucose biosensor 102 such formulated (new mediator and internal reference) can be operated at a high potential (+400 mV) to produce currents in a range that fits the calibration characteristics of the hardware requirements of the existing instrument. Secondly, since the lower redox potential and thus a lower oxidation power of the mediator will likely to have virtually no conversion of the oxidized form to the reduced form of the mediator, a lower operation potential (0-100 mV) can be applied to the sensor so as to avoid the oxidation of the internal reference. Thus, a new set of calibration characteristics based on the new mediator, most likely with near zero intercept due to the lower oxidation power, will lead to a better analytical precision for glucose measurements. It will also reduce the matrix interference in the whole blood by avoiding the oxidation of some of the known oxidizable species such as uric acid and acetaminophen.


In accordance with features of the invention, another application of the internal reference to glucose sensors 102 is to add adequately large amount of internal reference to the biosensor system to produce a high current response. Using the double steps algorithm with open circuit between them (Bayer U.S. Pat. Nos. 5,620,579 and 5,653,863), the first potential step is set at 400 mV to produce a current that is mostly due to the internal reference signal while the second step is set at a low potential (0-100 mV) to produce a current signal related to the glucose concentration only. The ratio of the first signal, which should be virtually independent of the whole blood hematocrit, to the second signal at low potential can be used to correct for the analytical bias due to hematocrit effect.


In accordance with features of the invention, the internal reference is defined as the oxidizable species which in one embodiment is further defined as the reduced form of a reversible redox couple that has an equal or higher redox potential than that of the mediator. The concept and use of an internal reference are very common in the field of analytical chemistry. However, no example of using an internal reference for biosensors has been suggested in existing patents or literature. In all three scenarios described above, the internal reference acts to increase the response current additively for operation potentials that oxidize both species and with glucose as the analyte; a total response current is represented by:

Itotal=Iint-ref+Iglucose
Iint-ref∝(internal reference) and Iglucose∝(glucose);

Where Iint-ref is the portion of the total response current due to the internal reference, while Iglucose is due to the oxidation of mediator proportional to the glucose concentration.


In accordance with features of the invention, the internal reference can be either the same mediator species or an oxidizable species with a higher redox potential than the mediator. Thus for biosensors with a low operation potential oxidizing only the mediator, the current Iint-ref will be zero. However, for biosensors with a higher operation potential that oxidizes both species, the total response current will be the sum of the portion due to internal reference and that due to glucose. Since the internal reference concentration is fixed, the calibration slope of the sensor will only depend on the sensor response for glucose while the intercept will depend on the added amount of the internal reference. In another words, the internal reference will only offset the intercept and will not change the calibration slope. Thus, the concept of internal reference provides new and different ways to make glucose biosensors.


Referring now to FIGS. 1B, 1C, and 1D, there are at least three modes of operation based on the use of internal reference for glucose biosensors 102 of the invention. Potentiostatically, the three of modes of operation are represented in FIGS. 1B, 1C, and 1D. Each of the illustrated modes of operation include a first burnoff pulse, followed by a second wait period or open circuit, and a final third read pulse, each pulse or period having a selected duration, for example, 10 seconds. In the basic and most immediate operation, ferrocyanide is retained in ferricyanide at the concentration of 0.1 to 1% of the total ferricyanide providing the internal reference for glucose biosensors 102 of the invention. This is depicted in FIG. 1B where both potentials in the first and the third periods are at the same voltage, for example 400 mV. Retaining of a small percentage of ferrocyanide defining the internal reference can be accomplished either by an appropriate purification process of ferricyanide or by adding an adequate amount of ferrocyanide to the pure ferricyanide. The outcome of these retaining processes is to keep deliberately a desirable amount of ferrocyanide in ferricyanide as a special grade of ferricyanide. This is in contrast to the conventional wisdom of having as pure a form of ferricyanide as possible, such as for the DEX reagent, usually ferrocyanide in the order of 0.05% of ferricyanide or less as impurity. The most desirable amount is 0.1% ferrocyanide in the final formulation for DEX sensor, which will lead to the anchoring of the calibration intercept at a narrower range while maintaining the calibration slope for the DEX sensor.


In FIG. 1C the second mode of operation is shown, where a desirable amount of ferrocyanide (the internal reference) is added to the reagent of enzyme and a mediator with a redox potential lower than that of the internal reference. The biosensor 102 is expected to work under high and low potentials (for example at 400 mV and 100 mV vs. Ag/AgCl) for existing instruments and instruments with a new hardware requirement. This biosensor can be operated in potential programs depicted in FIG. 1B for existing instruments 100 and FIG. 1C for new instruments 100. Examples of the mediator and internal reference combination include the system of MLB-92 and ferrocyanide as well as ruthenium hexaamine and ferrocyanide. The separation of the two redox potentials is large enough so that there will be generally no oxidation of the internal reference species when operated at the low voltage.


In FIG. 1D the third mode of operation is shown, where a higher but desirable concentration of ferrocyanide is added to the reagent mixture of enzyme and a mediator with a redox potential lower than that of the internal reference. The amount of the internal reference would produce a current equivalent to about 50% to 75% of the full scale in the calibration range preferably. In the operation algorithm, the first potential step is set to oxidize both the mediator and the internal reference (400 mV) while the second potential step for the read pulse is to oxidize the mediator only (0-100 mV). The current in the first potential step of FIG. 1D will be most pertinent to the internal reference that is immediately next to the electrode and should have virtually no hematocrit effect. The ratio of the current from the second step to that from the first step will provide a correction for the analytical bias due to hematocrit effect.


Experiments have been carried out to show the feasibility of the method of adding internal reference to a mediator system to overcome existing problems or to enhance sensor performance in accordance with the biosensor 102 of the invention.


Referring now to FIGS. 2A, 2B, and 2C, there are shown three cyclic voltammograms illustrating operation of the biosensor 102 of the invention. The illustrated three cyclic voltammograms are for MLB based glucose biosensors 102 with ferrocyanide as the internal reference in whole blood samples of 0 mg/dL glucose.



FIG. 2A illustrates working electrode vs. ferricyanide counter electrode, FIG. 2B illustrates working electrode vs. silver (Ag) and silver chloride (AgCl) or Ag/AgCl counter electrode and FIG. 2C illustrates working electrode vs. MLB-92 counter electrode. Respective peaks labeled 1 and 2 represent the oxidation of the mediator MLBred (reduced form of MLB) and the internal reference ferrocyanide respectively for all three voltammogram plots. The oxidation peak for MLBred shifts along the potential scale as the redox couple on the counter electrode changes from ferricyanide to Ag/AgCl to MLB-92. However, it can be seen that the relative position of the mediator MLB-92 to the internal reference ferrocyanide is the same in all three voltammogram plots of FIGS. 2A, 2B, and 2C.


Referring to FIG. 3, there shown in FIG. 3 is a chart illustrating a linear response of the biosensor 102 of the invention at different voltage operating potentials. The biosensor 102 is operated at (1) 400 mV potential and (2) 150 mV potential. FIG. 3 illustrates the linear dose response of MLB-92 mediator based biosensor 102 with 20 mM ferrocyanide as the internal reference. Respective lines labeled EXAMPLE 1 and EXAMPLE 2 are from 400 mV and 150 mV operation potentials against Ag/AgCl counter electrode. As shown in FIG. 3, the biosensor 102 gives virtually the same slope but with different intercepts for operations at 400 mV and 150 mV potentials. This result demonstrates that the internal reference can be selectively oxidized or avoided by the operation potential. Thus, one biosensor 102 can serve for two different meters.


Examples of the biosensor 102 have been prepared systematically showing the increase of intercept with increasing ferrocyanide as the internal reference while the slopes were kept virtually unchanged. Three working electrode reagents were prepared in the following formulations. These three reagents were pin-deposited on to two sensor formats: (1) Ag/AgCl as the counter electrode, (2) 10% printed ferricyanide as the counter electrode.

















Enzyme,

Internal




PQQ-
Mediator
Reference
Buffer and


Formulations
GDH
MLB-92
Ferricyanide
binding agent,







1
20 unit/μL
24 mM
0 mM
0.1M NaCl +






phosphate,






1% CMC


2
20 unit/μL
24 mM
4 mM
0.1M NaCl +






phosphate,






1% CMC


3
20 unit/μL
24 mM
8 mM
0.1M NaCl +






phosphate,






1% CMC










FIG. 4 illustrates effect of the added internal reference to the overall voltammetric current using biosensors 102 of the invention with 10% printed ferricyanide as the counter electrode. FIG. 4 provides cyclic voltammograms of sensors with ferrocyanide as the internal reference in whole blood samples of 0 mg/L glucose. Voltammograms labeled A, B and C are with formulations 1, 2 and 3 respectively all with a counter electrode of 10% printed ferricyanide.


The effect of the added internal reference to the overall voltammetric current is shown in FIG. 4 using sensors with 10% printed ferricyanide as the counter electrode. The main oxidation/reduction peaks here are centered around −0.38 Volt vs. 10% ferricyanide, which is due to the mediator MLB. The oxidation peak at about 0-50 mV is due to the internal reference of ferrocyanide. While the oxidation peak for the internal reference ferrocyanide increases with the increases of the internal reference concentration from 0 to 4 to 8 mM, the oxidation peak for the mediator is virtually unchanged. Here the concept of internal reference is explained further by the fact that the main oxidation peak of MLBred is unaffected by the presence of the internal reference.


Referring to FIGS. 5A and 5B, charts illustrating linear response and increased intercept with increasing internal reference of MLB based biosensors 102 of the invention with Ag/AgCl as the counter electrode are shown. FIG. 5A illustrates the linear dose response of MLB based biosensors 102 with 0, 4, and 8 mM ferrocyanide, respectively labeled EXAMPLE 1, EXAMPLE 2, and EXAMPLE 3. FIG. 5B illustrates intercept and slope as a function of added ferrocyanide in the working electrode reagent of the biosensor 102 of the invention. All three sensors used Ag/AgCl as the counter electrode.


Referring also to FIGS. 6A and 6B, charts illustrating linear response and increased intercept with increasing internal reference of MLB based biosensors 102 of the invention with 10% ferricyanide as the counter electrode are shown. FIG. 6A illustrates the linear dose response of MLB based biosensors 102 with 0, 4, and 8 mM ferrocyanide, respectively labeled EXAMPLE 1, EXAMPLE 2, and EXAMPLE 3. FIG. 6B illustrates intercept and slope as a function of added ferrocyanide in the working electrode reagent of the biosensor 102 of the invention. All three sensors used 10% printed ferricyanide as the counter electrode.


In the dose response experiments, both sensor series with Ag/AgCl counter electrode of FIGS. 5A and 5B, and 10% ferricyanide counter electrode of FIGS. 6A and 6B show linear response and increased intercept with increasing internal reference. For practical purpose, the slope of the three sensors in FIGS. 5A and 5B is unchanged while the intercept increases linearly with the added ferrocyanide. The same linear relationship of intercept with added ferrocyanide and the flat slope trend are repeated in sensor series with the % printed ferricyanide as the counter electrode, as shown in FIGS. 6A and 6B.


Experiments have been carried out to show the addition of ferrocyanide to DEX reagent ink, modification of calibration intercept without changing slope in accordance with the biosensor 102 of the invention.



FIG. 7 illustrates linear relationship of the calibration intercept with increasing internal reference of DEX type biosensors 102 of the invention. Five different formulations in a set format labeled BC7 in FIG. 7 were made with 0, 0.02, 0.04, 0.06 and 0.08% ferrocyanide mixed in the standard DEX reagent for the DEX sensor. The regression slope and intercepts for these five sensors of the BC7 format are shown in FIG. 7. Except for sensor with 0.06% ferrocyanide due to the experimental problems, the intercepts of the other four sensors give a nice linear function with respect to the added amount of ferrocyanide as the internal reference. On the other hand, the slopes of all five sensors fall in a flat line indicating that the addition of the internal reference does not change the slope of the DEX type biosensors 102 of the invention.



FIGS. 8A and 8B illustrate the ratio of signal to reference results from flow-injection-analysis (FIA) of the residual ferrocyanide from a control reagent ink and the reagent ink with 0.1% ferrocyanide added to the reagent mixture of 20% ferricyanide of a biosensor 102 of the invention. One of the subtle effects of adding the internal reference ferrocyanide to the DEX reagent ink is to decrease the driving force for the conversion of the mediator ferricyanide to ferrocyanide. Thus, ferricyanide becomes the source of the residual current in the DEX sensor. One way of showing this subtle effect is to monitor the increase of the residual current (background current) of the reagent ink with internal reference along with the control reagent ink over a long period of time. Both reagent inks were stored in refrigeration (2-8° C.) over several weeks. FIG. 8 shows the results of FIA of the residual ferrocyanide from both reagent inks. From FIG. 8, the ratio of signal-to-reference (S/R) represents the relative amount of ferrocyanide from the reagent ink compared to the added ferrocyanide as the reference in FIA. Thus, the higher the value of S/R from the FIA analysis, the higher the ferrocyanide in the reagent inks. It can be seen from FIG. 8A that the S/R value increase over the period of six weeks for both the control inks and the reagent ink with added ferrocyanide. However, the reagent ink curve with added ferrocyanide has a slower increase of residual current over the period of six weeks compared to control curves. In FIG. 8B, the S/R response curves from the control inks and the reagent ink with added ferrocyanide are merged together for comparison. To the first order approximation (since the coefficients for the second order terms of both second order polynomials are very small), the rate of residual current increase over six weeks during refrigeration is about 30% ([0.0918−0.0638]/0.0918=30%) smaller for the reagent ink curve with added ferrocyanide than for the control curves. Thus, it may be understood from FIGS. 8A and 8B that the rate of the ferricyanide-to-ferrocyanide conversion in reagent ink is decreased substantially by the addition of the internal reference ferrocyanide to the DEX reagent ink in accordance with biosensor 102 of the invention.


While the present invention has been described with reference to the details of the embodiments of the invention shown in the drawings, these details are not intended to limit the scope of the invention as claimed in the appended claims.

Claims
  • 1. A method of using a biosensor including a mixture of an only one enzyme, a mediator, and an oxidizable species as an internal reference, said oxidizable species being different than the mediator species and having different redox potentials, wherein said mixture is located directly on a surface of at least a portion of a working electrode, said method comprising the steps of: applying a first voltage potential in a first voltage period;providing a set delay period;applying a second voltage potential in a second voltage period following said delay period; and wherein said first voltage potential and said second voltage potential are selectively provided for oxidizing only said mediator or both said mediator and said internal reference.
  • 2. The method of claim 1 wherein the step of applying said first voltage potential in said first voltage period includes the step of applying a selected first voltage potential in said first voltage period for oxidizing said mediator and said internal reference.
  • 3. The method of claim 1 wherein the step of applying said first voltage potential in said first voltage period includes the step of applying a selected first voltage potential in said first voltage period for oxidizing only said mediator.
  • 4. The method of claim 1 wherein the step of applying said second voltage potential in said second voltage period following said delay period includes the step of applying a selected second voltage potential for oxidizing said mediator and said internal reference.
  • 5. The method of claim 1 wherein the step of applying said second voltage potential in said second voltage period following said delay period includes the step of applying a selected second voltage potential for oxidizing only said mediator.
  • 6. The method of claim 1 wherein the steps of applying said first voltage potential and applying said second voltage potential includes the steps of applying a selected voltage potential in a range between 100 mV and 400 mV.
  • 7. The method of claim 1 wherein the steps of applying said first voltage potential and applying said second voltage potential includes the steps of applying a selected first voltage potential in said first voltage period for oxidizing both said mediator and said internal reference; and applying a selected second voltage potential for oxidizing only said mediator.
  • 8. The method of claim 1 wherein the biosensor includes a mediator comprising 3-phenylimino-3H-phenothiazine; and wherein said internal reference comprises ferrocyanide.
  • 9. The method of claim 1 wherein the steps of applying said first voltage potential and applying said second voltage potential includes the steps of applying a selected first and second voltage potential for oxidizing both said mediator and said internal reference; wherein said internal reference effectively anchoring a calibration intercept within a narrow range and said internal reference effectively maintaining a calibration slope for the biosensor.
  • 10. The method of claim 1 wherein said mediator comprises ruthenium hexamine, and wherein said internal reference comprises ferrocyanide.
  • 11. The method of claim 1 wherein said internal reference comprises ferrocyanide.
  • 12. The method of claim 1 wherein said mediator comprises 3-phenylimino-3H-phenothiazine.
  • 13. The method of claim 1 wherein said mediator comprises ruthenium hexaamine.
  • 14. The method of claim 1 wherein the steps of applying said first voltage potential and applying said second voltage potential includes the steps of applying a selected voltage potential in a range between 0 mV and 400 mV.
  • 15. A method of using a biosensor to assist in determining glucose concentration, the method comprising: providing a biosensor including a reagent, located directly on a surface of at least a portion of a working electrode, the reagent including an only one enzyme, mediator and an oxidizable species as an internal reference, said oxidizable species being different than the mediator species and having different redox potentials;applying a first voltage potential in a first voltage period;providing a set delay period; andapplying a second voltage potential in a second voltage period following said delay period,wherein said first voltage potential is selectively provided for oxidizing only said mediator or both said mediator and said internal reference, and wherein said second voltage potential is selectively provided for oxidizing only said mediator or both said mediator and said internal reference.
  • 16. The method of claim 15 wherein the enzyme includes glucose oxidase.
  • 17. The method of claim 15 wherein enzyme includes glucose dehydrogenase.
  • 18. The method of claim 15 wherein said mediator reference comprises 3-phenylimino-3H-phenothiazine.
  • 19. The method of claim 18 wherein said internal reference is ferrocyanide.
  • 20. The method of claim 15 wherein the steps of applying said first voltage potential and applying said second voltage potential includes the steps of applying a selected voltage potential in a range between 0 mV and 400 mV.
  • 21. A method of using a biosensor to assist in determining an analyte concentration, the method comprising: providing a biosensor including a reagent, the reagent, located directly on a surface of at least a portion of the working electrode, including only one enzyme, mediator and an oxidizable species as an internal reference;applying a first voltage potential in a first voltage period;providing a set delay period; and applying a second voltage potential in a second voltage period following said delay period;wherein one of said first voltage potential and said second voltage potential oxidizes only said mediator and the other one of said first voltage potential and said second voltage potential oxidizes both said mediator and said internal reference.
  • 22. The method of claim 21 wherein the analyte is glucose.
  • 23. The method of claim 22 wherein the enzyme includes glucose oxidase or glucose dehydrogenase.
  • 24. The method of claim 21 wherein said mediator reference comprises 3-phenylimino-3H-phenothiazine.
  • 25. The method of claim 21 wherein the steps of applying said first voltage potential and applying said second voltage potential includes the steps of applying a selected voltage potential in a range between 100 mV and 400 mV.
  • 26. The method of claim 21 wherein said first voltage potential oxidizes both said mediator and said internal reference and said second voltage potential oxidizes only said internal reference.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 10/590,867 filed Aug. 24, 2006, which has been allowed; application Ser. No. 10/590,867 filed Aug. 24, 2006 is a nationalized application of Application No. PCT/US2005/03622 filed Feb. 4, 2005, which claims priority to Application No. 60/542,362 filed on Feb. 6, 2004, which are all incorporated by reference in their entireties.

US Referenced Citations (676)
Number Name Date Kind
3420205 Morrison Jan 1969 A
3505136 Attwood Apr 1970 A
3510268 Hach May 1970 A
3551295 Dyer Dec 1970 A
3573139 Eiji Mori et al. Mar 1971 A
3621381 Eckfeldt Nov 1971 A
3715192 Wenz et al. Feb 1973 A
3720093 Gill Mar 1973 A
3763422 MacPhee et al. Oct 1973 A
3770607 Williams Nov 1973 A
3776832 Oswin et al. Dec 1973 A
3791933 Moyer et al. Feb 1974 A
3791988 Bauer et al. Feb 1974 A
3838033 Mindt et al. Sep 1974 A
3902970 Levin Sep 1975 A
3917453 Milligan et al. Nov 1975 A
3919627 Allen Nov 1975 A
3920580 Mast Nov 1975 A
3925183 Oswin et al. Dec 1975 A
3937615 Clack et al. Feb 1976 A
3948745 Guillbault et al. Apr 1976 A
3980437 Kishimoto et al. Sep 1976 A
4005002 Racine et al. Jan 1977 A
4008448 Muggli Feb 1977 A
4040908 Clark, Jr. Aug 1977 A
4053381 Hamblen et al. Oct 1977 A
4065263 Woodbridge et al. Dec 1977 A
4077861 Lauer Mar 1978 A
4123701 Josefsen et al. Oct 1978 A
4127448 Schick et al. Nov 1978 A
4137495 Brown Jan 1979 A
4184936 Paul et al. Jan 1980 A
4214968 Battaglia et al. Jul 1980 A
4217196 Huch Aug 1980 A
4224125 Nakamura et al. Sep 1980 A
4225410 Pace et al. Sep 1980 A
4229426 Haagensen, Jr. Oct 1980 A
4230537 Delente et al. Oct 1980 A
4233029 Columbus Nov 1980 A
4260680 Muramatsu et al. Apr 1981 A
4263343 Kim Apr 1981 A
4265250 Parker May 1981 A
4273639 Gottermeier Jun 1981 A
4297184 Dyer Oct 1981 A
4297569 Flies Oct 1981 A
4301412 Hill et al. Nov 1981 A
4303887 Hill et al. Dec 1981 A
4304853 Jozefonvicz et al. Dec 1981 A
4323536 Columbus Apr 1982 A
4329642 Luthi et al. May 1982 A
4366033 Richter et al. Dec 1982 A
4376689 Nakamura et al. Mar 1983 A
4381775 Nose et al. May 1983 A
4396464 Giner et al. Aug 1983 A
4402940 Nose et al. Sep 1983 A
4403984 Ash et al. Sep 1983 A
4407290 Wiber Oct 1983 A
4407959 Tsuji et al. Oct 1983 A
4413407 Columbus Nov 1983 A
4420564 Tsuji et al. Dec 1983 A
4431004 Bessman et al. Feb 1984 A
4436094 Cerami Mar 1984 A
4440175 Wilkins Apr 1984 A
4473457 Columbus Sep 1984 A
4476149 Poppe et al. Oct 1984 A
4477314 Richter et al. Oct 1984 A
4477575 Vogel et al. Oct 1984 A
4490216 McConnell Dec 1984 A
4499423 Matthiessen Feb 1985 A
4502938 Covington et al. Mar 1985 A
4517291 Seago May 1985 A
4545382 Higgins et al. Oct 1985 A
4547735 Kiesewetter et al. Oct 1985 A
4552458 Lowne Nov 1985 A
4561944 Sasaki et al. Dec 1985 A
4571292 Liu et al. Feb 1986 A
4572899 Walker et al. Feb 1986 A
4578716 Van Rijckevorsel et al. Mar 1986 A
4579893 Wang et al. Apr 1986 A
4582684 Vogel et al. Apr 1986 A
4591550 Hafeman et al. May 1986 A
4628193 Blum Dec 1986 A
4642295 Baker Feb 1987 A
4648665 Davis et al. Mar 1987 A
4652830 Brown Mar 1987 A
4654197 Lilja et al. Mar 1987 A
4671288 Gough Jun 1987 A
4676653 Strohmeier et al. Jun 1987 A
4679562 Luksha Jul 1987 A
4680268 Clark, Jr. Jul 1987 A
4682602 Prohaska Jul 1987 A
4686479 Young et al. Aug 1987 A
4703017 Campbell et al. Oct 1987 A
4703756 Gough et al. Nov 1987 A
4713347 Mitchell et al. Dec 1987 A
4714874 Morris et al. Dec 1987 A
4721677 Clark, Jr. Jan 1988 A
4729959 Ryan Mar 1988 A
4731726 Allen et al. Mar 1988 A
4734184 Burleigh et al. Mar 1988 A
4745076 Muller et al. May 1988 A
4746607 Mura et al. May 1988 A
4750496 Reinhart et al. Jun 1988 A
4759828 Young et al. Jul 1988 A
4795542 Ross et al. Jan 1989 A
4797256 Watlington, IV Jan 1989 A
4805624 Yao et al. Feb 1989 A
4806311 Greenquist Feb 1989 A
4806312 Greenquist Feb 1989 A
4810203 Komatsu Mar 1989 A
4816224 Vogel et al. Mar 1989 A
4820399 Senda et al. Apr 1989 A
4820636 Hill et al. Apr 1989 A
4830959 McNeil et al. May 1989 A
4832814 Root May 1989 A
4834234 Sacherer et al. May 1989 A
4849330 Humphries et al. Jul 1989 A
4854153 Miyagawa et al. Aug 1989 A
4865873 Cole, Jr. et al. Sep 1989 A
4877580 Aronowitz et al. Oct 1989 A
4890926 Dosmann et al. Jan 1990 A
4894137 Takizawa et al. Jan 1990 A
4897162 Lewandowski et al. Jan 1990 A
4919770 Preidel et al. Apr 1990 A
4927516 Yamaqucji et al. May 1990 A
4929330 Osaka et al. May 1990 A
4929545 Freitage May 1990 A
4935105 Churchouse Jun 1990 A
4935106 Liston et al. Jun 1990 A
4936346 Kugler Jun 1990 A
4938860 Wogoman Jul 1990 A
4940945 Littlejohn et al. Jul 1990 A
4954087 Lauks et al. Sep 1990 A
4956275 Zuk et al. Sep 1990 A
4963814 Parks et al. Oct 1990 A
4970145 Bennetto et al. Nov 1990 A
4975647 Downer et al. Dec 1990 A
4976724 Nieto Dec 1990 A
4999582 Parks et al. Mar 1991 A
4999632 Parks Mar 1991 A
5018164 Brewer et al. May 1991 A
5019974 Beckers May 1991 A
5028542 Kennamer et al. Jul 1991 A
5035862 Dietze et al. Jul 1991 A
5039618 Stone Aug 1991 A
5046618 Wood Sep 1991 A
5049487 Phillips et al. Sep 1991 A
5057447 Paterson et al. Oct 1991 A
5059199 Okada et al. Oct 1991 A
5059394 Phillips et al. Oct 1991 A
5066372 Weetall Nov 1991 A
5075077 Durley, III et al. Dec 1991 A
5096669 Lauks et al. Mar 1992 A
5096671 Kane et al. Mar 1992 A
5108564 Szuminsky et al. Apr 1992 A
5108819 Heller et al. Apr 1992 A
5112455 Cozzette et al. May 1992 A
5112758 Fellman et al. May 1992 A
5118183 Cargill et al. Jun 1992 A
5120420 Nankai et al. Jun 1992 A
5120421 Glass et al. Jun 1992 A
5122244 Hoenes et al. Jun 1992 A
5128015 Szuminsky et al. Jul 1992 A
5140176 Okino Aug 1992 A
5141850 Cole et al. Aug 1992 A
5141868 Shanks et al. Aug 1992 A
5143694 Schafer et al. Sep 1992 A
5155628 Dosmann Oct 1992 A
5179005 Phillips et al. Jan 1993 A
5179288 Miffitt et al. Jan 1993 A
5182707 Cooper et al. Jan 1993 A
5187100 Matzinger et al. Feb 1993 A
5192415 Yosioka et al. Mar 1993 A
5202261 Musho et al. Apr 1993 A
5206147 Hoenes Apr 1993 A
5217594 Henkens et al. Jun 1993 A
5220920 Gharib Jun 1993 A
5223117 Wrighton et al. Jun 1993 A
5229282 Yoshioka et al. Jul 1993 A
5232516 Hed Aug 1993 A
5232667 Hieb et al. Aug 1993 A
5232668 Grante et al. Aug 1993 A
5234813 MeGreenhan et al. Aug 1993 A
5243516 White Sep 1993 A
5246858 Arbuckle et al. Sep 1993 A
5250439 Musho et al. Oct 1993 A
5261411 Hughes et al. Nov 1993 A
5262035 Gregg et al. Nov 1993 A
5264103 Yoshioka et al. Nov 1993 A
5264104 Gregg et al. Nov 1993 A
5266179 Nanki et al. Nov 1993 A
5269891 Colin Dec 1993 A
5279294 Anderson et al. Jan 1994 A
5281395 Markart et al. Jan 1994 A
5282950 Dietze et al. Feb 1994 A
5284770 Adrain et al. Feb 1994 A
5286362 Hoenes et al. Feb 1994 A
5288387 Ito et al. Feb 1994 A
5288636 Pollmann et al. Feb 1994 A
5304468 Phillips et al. Apr 1994 A
5306623 Kiser et al. Apr 1994 A
5311426 Donohue et al. May 1994 A
5312590 Gunasingham May 1994 A
5320725 Gregg et al. Jun 1994 A
5320732 Nankai et al. Jun 1994 A
5321492 Detwiler et al. Jun 1994 A
5332479 Uenoyama et al. Jul 1994 A
5334296 Henkens et al. Aug 1994 A
5344754 Zewing Sep 1994 A
5352351 White et al. Oct 1994 A
5353351 Bartoli et al. Oct 1994 A
5354447 Uenoyama et al. Oct 1994 A
5356786 Heller et al. Oct 1994 A
5361314 Kopelman et al. Nov 1994 A
5366609 White et al. Nov 1994 A
5368707 Henkens et al. Nov 1994 A
5371687 Holmes, II et al. Dec 1994 A
5376254 Fisher Dec 1994 A
5379214 Arbuckle et al. Jan 1995 A
5384028 Ito Jan 1995 A
5385846 Kuhn et al. Jan 1995 A
5389215 Horiuchi et al. Feb 1995 A
5391272 O'Daly et al. Feb 1995 A
5393903 Gratzel et al. Feb 1995 A
5395504 Saurer et al. Mar 1995 A
5403462 Lev et al. Apr 1995 A
5405511 White et al. Apr 1995 A
5410059 Fraser et al. Apr 1995 A
5410474 Fox Apr 1995 A
5411647 Johnson et al. May 1995 A
5413690 Kost et al. May 1995 A
5413764 Haar May 1995 A
5418142 Kiser et al. May 1995 A
5421189 Dussault Jun 1995 A
5424035 Hones et al. Jun 1995 A
5426032 Phillips et al. Jun 1995 A
5427912 Brown et al. Jun 1995 A
5429735 Johnson et al. Jul 1995 A
5437772 DeCastro et al. Aug 1995 A
5437999 Diebold et al. Aug 1995 A
5438271 White et al. Aug 1995 A
5439826 Kontorovich Aug 1995 A
5445967 Deuter Aug 1995 A
5447837 Urnovitz Sep 1995 A
5449898 Dosmann Sep 1995 A
5453360 Yu Sep 1995 A
5468366 Wegner et al. Nov 1995 A
5469846 Khan Nov 1995 A
5470533 Shindo et al. Nov 1995 A
5477326 Dosmann Dec 1995 A
5489414 Schreiber et al. Feb 1996 A
5494638 Gullick Feb 1996 A
5500350 Baker et al. Mar 1996 A
5502396 Desarzens et al. Mar 1996 A
5504011 Gavin et al. Apr 1996 A
5508171 Walling et al. Apr 1996 A
5508200 Tiffany et al. Apr 1996 A
5508203 Fuller et al. Apr 1996 A
5509410 Hill et al. Apr 1996 A
5512159 Yoshioka et al. Apr 1996 A
5515847 Braig et al. May 1996 A
5518689 Dosmann et al. May 1996 A
5520786 Bloczynski et al. May 1996 A
5526111 Collins et al. Jun 1996 A
5526120 Jina et al. Jun 1996 A
5526808 Kaminsky Jun 1996 A
5532128 Eggers et al. Jul 1996 A
5545519 Vadagama et al. Aug 1996 A
5552116 Yokota et al. Sep 1996 A
5554531 Zweig Sep 1996 A
5556789 Goerlach-Graw et al. Sep 1996 A
5563031 Yu Oct 1996 A
5563042 Phillips et al. Oct 1996 A
5569591 Kell et al. Oct 1996 A
5569608 Sommer Oct 1996 A
5572159 McFarland Nov 1996 A
5575403 Charlton et al. Nov 1996 A
5575895 Ikeda et al. Nov 1996 A
5576073 Kickelhain Nov 1996 A
5580794 Allen Dec 1996 A
5582697 Ikeda et al. Dec 1996 A
5589045 Hyodo Dec 1996 A
5589326 Deng et al. Dec 1996 A
5593390 Castellano et al. Jan 1997 A
5593739 Kickelhain Jan 1997 A
5594906 Holmes, II et al. Jan 1997 A
5597532 Connolly Jan 1997 A
5603820 Malinski et al. Feb 1997 A
5604110 Baker et al. Feb 1997 A
5605662 Heller et al. Feb 1997 A
5605837 Karimi et al. Feb 1997 A
5611909 Studer Mar 1997 A
5611999 Dosmann et al. Mar 1997 A
5620579 Genshaw et al. Apr 1997 A
5620863 Tomasco et al. Apr 1997 A
5620890 Kamps-Holtzapple et al. Apr 1997 A
5627922 Kopelman et al. May 1997 A
5628890 Carter et al. May 1997 A
5630986 Charlton et al. May 1997 A
5635362 Levine et al. Jun 1997 A
5635364 Clark et al. Jun 1997 A
5639671 Bogart et al. Jun 1997 A
5642734 Ruben et al. Jul 1997 A
5644501 Lin et al. Jul 1997 A
5645798 Schreiber et al. Jul 1997 A
5650061 Kuhr et al. Jul 1997 A
5650062 Ikeda et al. Jul 1997 A
5653863 Genshaw et al. Aug 1997 A
5654178 Fitzpatrick et al. Aug 1997 A
5656502 Mackay et al. Aug 1997 A
5658443 Yamamoto et al. Aug 1997 A
5658802 Hayes et al. Aug 1997 A
5660791 Brenneman et al. Aug 1997 A
5665215 Bussmann et al. Sep 1997 A
5670031 Hintsche et al. Sep 1997 A
5682884 Hill et al. Nov 1997 A
5686659 Neel et al. Nov 1997 A
5691486 Behringer et al. Nov 1997 A
5691633 Liu et al. Nov 1997 A
5695623 Michel et al. Dec 1997 A
5695947 Guo et al. Dec 1997 A
5698083 Glass Dec 1997 A
5700695 Yassinzadeh et al. Dec 1997 A
5701181 Boiarski et al. Dec 1997 A
5704354 Preidel et al. Jan 1998 A
5708247 McAleer et al. Jan 1998 A
5710011 Forrow et al. Jan 1998 A
5710622 Neel et al. Jan 1998 A
5719667 Miers Feb 1998 A
5720862 Hamamoto et al. Feb 1998 A
5723284 Ye Mar 1998 A
5723345 Yamauchi et al. Mar 1998 A
5727548 Hill et al. Mar 1998 A
5728074 Castellano et al. Mar 1998 A
5745308 Spangenberg et al. Apr 1998 A
5748002 Scott et al. May 1998 A
5755953 Henning et al. May 1998 A
5757666 Schreiber et al. May 1998 A
5759364 Charlton et al. Jun 1998 A
5759794 Levine et al. Jun 1998 A
5762770 Pritchard et al. Jun 1998 A
5776710 Levine et al. Jul 1998 A
5780304 Matzinger et al. Jul 1998 A
5786584 Button et al. Jul 1998 A
5788833 Lewis et al. Aug 1998 A
5789255 Yu Aug 1998 A
5792668 Fuller et al. Aug 1998 A
5798031 Charlton et al. Aug 1998 A
5801057 Smart et al. Sep 1998 A
5807375 Gross et al. Sep 1998 A
5820551 Hill et al. Oct 1998 A
5820662 Kubo et al. Oct 1998 A
5832921 Lennert et al. Nov 1998 A
5834217 Levine et al. Nov 1998 A
5837546 Allen et al. Nov 1998 A
5843691 Douglas et al. Dec 1998 A
5843692 Phillips et al. Dec 1998 A
5846794 Delobeau et al. Dec 1998 A
5849174 Sanghera et al. Dec 1998 A
5856195 Charlton et al. Jan 1999 A
5863400 Drummond et al. Jan 1999 A
5873990 Wojciechowski et al. Feb 1999 A
5874046 Megerle et al. Feb 1999 A
5883378 Irish et al. Mar 1999 A
5885839 Lingane et al. Mar 1999 A
5890489 Elden Apr 1999 A
5904898 Market May 1999 A
5911872 Lewis et al. Jun 1999 A
5916156 Hildenbrand et al. Jun 1999 A
5921925 Cartmell et al. Jul 1999 A
5922530 Yu Jul 1999 A
5922591 Anderson et al. Jul 1999 A
5925021 Castellano et al. Jul 1999 A
RE36268 Szuminsky et al. Aug 1999 E
5942102 Hodges et al. Aug 1999 A
5945341 Howard, III Aug 1999 A
5948289 Noda et al. Sep 1999 A
5958199 Miyamto et al. Sep 1999 A
5965380 Heller et al. Oct 1999 A
5968760 Phillips et al. Oct 1999 A
5971923 Finger Oct 1999 A
5989917 McAleer et al. Nov 1999 A
6001239 Douglas et al. Dec 1999 A
6004441 Fujiwara et al. Dec 1999 A
6004442 Choulga et al. Dec 1999 A
6013170 Meade Jan 2000 A
6033866 Guo et al. Mar 2000 A
6042714 Lin et al. Mar 2000 A
6044285 Chaiken et al. Mar 2000 A
6045567 Taylor et al. Apr 2000 A
6054039 Shieh Apr 2000 A
6061128 Zweig et al. May 2000 A
6069011 Riedel May 2000 A
6071391 Gotoh et al. Jun 2000 A
6087182 Jeng et al. Jul 2000 A
6091975 Daddona et al. Jul 2000 A
6102872 Doneen et al. Aug 2000 A
6103033 Say et al. Aug 2000 A
6103509 Sode Aug 2000 A
6110354 Saban et al. Aug 2000 A
6120676 Heller et al. Sep 2000 A
6121009 Heller et al. Sep 2000 A
6121050 Han Sep 2000 A
6126609 Keith et al. Oct 2000 A
6128519 Say Oct 2000 A
6129823 Hughes et al. Oct 2000 A
6134461 Say et al. Oct 2000 A
6136549 Feistel Oct 2000 A
6136610 Polito et al. Oct 2000 A
6143164 Heller et al. Nov 2000 A
6143247 Sheppard, Jr. et al. Nov 2000 A
6144869 Berner et al. Nov 2000 A
6150124 Riedel Nov 2000 A
6153069 Pottgen et al. Nov 2000 A
6156051 Schraga Dec 2000 A
6156173 Gotoh et al. Dec 2000 A
6156673 Hintermaier et al. Dec 2000 A
6157442 Raskas Dec 2000 A
6157472 Eum et al. Dec 2000 A
6159745 Roberts et al. Dec 2000 A
6162611 Heller et al. Dec 2000 A
6162639 Douglas Dec 2000 A
6168563 Brown Jan 2001 B1
6168957 Matzinger et al. Jan 2001 B1
6170318 Lewis Jan 2001 B1
6174420 Hodges et al. Jan 2001 B1
6175752 Say et al. Jan 2001 B1
6176988 Kessler Jan 2001 B1
6179979 Hodges et al. Jan 2001 B1
6180062 Naka et al. Jan 2001 B1
6181417 Dosmann Jan 2001 B1
6193873 Oharra et al. Feb 2001 B1
6197040 LeVaughn et al. Mar 2001 B1
6200773 Ouyang et al. Mar 2001 B1
6201607 Roth et al. Mar 2001 B1
6203952 O'Brian et al. Mar 2001 B1
6206282 Hayes, Sr. et al. Mar 2001 B1
6206292 Roberts et al. Mar 2001 B1
6207000 Schwobel et al. Mar 2001 B1
6212417 Ikeda et al. Apr 2001 B1
6218571 Zhena et al. Apr 2001 B1
6225078 Ikeda et al. May 2001 B1
6226081 Fantone et al. May 2001 B1
6233471 Berner et al. May 2001 B1
6241862 McAleer et al. Jun 2001 B1
6246862 Grivas et al. Jun 2001 B1
6246966 Perry Jun 2001 B1
6251260 Heller et al. Jun 2001 B1
6258229 Winarta et al. Jul 2001 B1
6259937 Schulman et al. Jul 2001 B1
6261519 Harding et al. Jul 2001 B1
6262749 Finger et al. Jul 2001 B1
6268162 Phillips et al. Jul 2001 B1
6270637 Crismore et al. Aug 2001 B1
6271044 Ballerstadt et al. Aug 2001 B1
6272262 Kopelman et al. Aug 2001 B1
6272364 Kurnok Aug 2001 B1
6275717 Gross et al. Aug 2001 B1
6277641 Yager Aug 2001 B1
6281006 Heller et al. Aug 2001 B1
6284125 Hodges et al. Sep 2001 B1
6284550 Carroll et al. Sep 2001 B1
6287451 Winarta et al. Sep 2001 B1
6287595 Loewy et al. Sep 2001 B1
6294062 Buck et al. Sep 2001 B1
6294281 Heller Sep 2001 B1
6294787 Schieferdecker et al. Sep 2001 B1
6295506 Heinonen et al. Sep 2001 B1
6297697 Delano et al. Oct 2001 B2
6299757 Feldman et al. Oct 2001 B1
6300123 Vadgama et al. Oct 2001 B1
6300961 Finger et al. Oct 2001 B1
6309526 Fujiwara et al. Oct 2001 B1
6315951 Markart Nov 2001 B1
6316264 Corey et al. Nov 2001 B1
6326160 Dunn et al. Dec 2001 B1
6329161 Heller et al. Dec 2001 B1
6330464 Colvin, Jr. et al. Dec 2001 B1
6335203 Patel et al. Jan 2002 B1
6338790 Feldman et al. Jan 2002 B1
6340428 Ikeada et al. Jan 2002 B1
6342364 Watanabe et al. Jan 2002 B1
6344133 Formica et al. Feb 2002 B1
6349230 Kawanaka et al. Feb 2002 B1
6358752 Durst et al. Mar 2002 B1
6377896 Sato et al. Apr 2002 B1
6379513 Chambers et al. Apr 2002 B1
6389891 D'Angelico et al. May 2002 B1
6391558 Henkens et al. May 2002 B1
6391645 Huang et al. May 2002 B1
6394952 Anderson et al. May 2002 B1
6395227 Kiser et al. May 2002 B1
6399258 O'Brien et al. Jun 2002 B2
6401532 Lubbers Jun 2002 B2
6413398 Gerhardt et al. Jul 2002 B1
6413411 Pottgen et al. Jul 2002 B1
6414213 Ohmori et al. Jul 2002 B2
6414395 Ookuma et al. Jul 2002 B1
6414410 Nakamura et al. Jul 2002 B1
6420128 Ouyang et al. Jul 2002 B1
6444115 Hodges et al. Sep 2002 B1
6447657 Bhullar et al. Sep 2002 B1
6454921 Hodges et al. Sep 2002 B1
6461496 Feldman et al. Oct 2002 B1
6475372 Ohara et al. Nov 2002 B1
6484046 Say et al. Nov 2002 B1
6485923 Yani et al. Nov 2002 B1
6488827 Shartle Dec 2002 B1
6489133 Phillips et al. Dec 2002 B2
6491803 Shen et al. Dec 2002 B1
6491870 Patel et al. Dec 2002 B2
6501976 Sohrab Dec 2002 B1
6503381 Gotoh et al. Jan 2003 B1
6512986 Harmon Jan 2003 B1
6514718 Heller et al. Feb 2003 B2
6521110 Hodges et al. Feb 2003 B1
6521182 Shartle et al. Feb 2003 B1
6525330 Paolini et al. Feb 2003 B2
6525549 Poellmann Feb 2003 B1
6526298 Khalil et al. Feb 2003 B1
6531040 Musho et al. Mar 2003 B2
6531239 Heller Mar 2003 B2
6531322 Jurik et al. Mar 2003 B1
6535753 Raskas Mar 2003 B1
6537498 Lewis et al. Mar 2003 B1
6538735 Duebendorfer et al. Mar 2003 B1
6540890 Bhullar et al. Apr 2003 B1
6540891 Stewart et al. Apr 2003 B1
6541266 Modzelewski et al. Apr 2003 B2
6544474 Douglas et al. Apr 2003 B2
6549796 Sohrab Apr 2003 B2
6551494 Feldman et al. Apr 2003 B1
6555061 Leong et al. Apr 2003 B1
6558528 Matzinger May 2003 B1
6558529 McVey et al. May 2003 B1
6560471 Heller et al. May 2003 B1
6562625 Modzelewski et al. May 2003 B2
6565509 Haller et al. May 2003 B1
6565738 Henning et al. May 2003 B1
6570390 Hirayama et al. May 2003 B2
6571651 Hodges Jun 2003 B1
6572822 Jurki et al. Jun 2003 B2
6574425 Weiss et al. Jun 2003 B1
6576101 Heller et al. Jun 2003 B1
6576416 Haviland et al. Jun 2003 B2
6576461 Heller et al. Jun 2003 B2
6579690 Bonnecaze Jun 2003 B1
6591125 Buse et al. Jul 2003 B1
6592744 Hodges et al. Jul 2003 B1
6592745 Feldmen et al. Jul 2003 B1
6594514 Berner et al. Jul 2003 B2
6599407 Taniike et al. Jul 2003 B2
6600997 Deweese et al. Jul 2003 B2
6605200 Mao et al. Aug 2003 B1
6605201 Mao et al. Aug 2003 B1
6607658 Heller et al. Aug 2003 B1
6616819 Liamos et al. Sep 2003 B1
6618934 Feldmen et al. Sep 2003 B1
6623501 Heller et al. Sep 2003 B2
6627057 Bullar et al. Sep 2003 B1
6632349 Hodges et al. Oct 2003 B1
6636652 Kopelman et al. Oct 2003 B1
6638415 Hodges et al. Oct 2003 B1
6638716 Heller et al. Oct 2003 B2
6645359 Bhullar et al. Nov 2003 B1
6645368 Beaty et al. Nov 2003 B1
6654625 Say et al. Nov 2003 B1
6656702 Yugawa et al. Dec 2003 B1
6676816 Mao et al. Jan 2004 B2
6676995 Dick et al. Jan 2004 B2
6689265 Heller et al. Feb 2004 B2
6689411 Dick et al. Feb 2004 B2
6690836 Natarajan et al. Feb 2004 B2
6699384 Lin et al. Mar 2004 B1
6749740 Liamos et al. Jun 2004 B2
6767441 Cai et al. Jul 2004 B1
6790341 Saba et al. Sep 2004 B1
6824669 Choong et al. Nov 2004 B1
6824670 Tokunaga et al. Nov 2004 B2
6841052 Musho et al. Jan 2005 B2
6890421 Oharra et al. May 2005 B2
6893545 Gotoh et al. May 2005 B2
6942518 Liamos et al. Sep 2005 B2
7018843 Heller Mar 2006 B2
7122111 Tokunaga et al. Oct 2006 B2
7132041 Deng et al. Nov 2006 B2
7276146 Wilsey Oct 2007 B2
7351323 Iketaki et al. Apr 2008 B2
8026104 Wu et al. Sep 2011 B2
8088272 Deng Jan 2012 B2
8101062 Deng Jan 2012 B2
8147674 Wu Apr 2012 B2
8234076 Carpenter et al. Jul 2012 B2
8262899 Wu Sep 2012 B2
8287717 Wu Oct 2012 B2
8404100 Wu Mar 2013 B2
8425757 Wu et al. Apr 2013 B2
8470604 Wu et al. Jun 2013 B2
20010000129 Raskas Apr 2001 A1
20010006149 Taniike et al. Jul 2001 A1
20010017269 Heller et al. Aug 2001 A1
20010042683 Musho et al. Nov 2001 A1
20010052470 Hodges et al. Dec 2001 A1
20020004106 Leddy et al. Jan 2002 A1
20020012821 Leddy et al. Jan 2002 A1
20020053523 Liamos et al. May 2002 A1
20020079219 Zhao et al. Jun 2002 A1
20020081588 De Lumley-Woodyear et al. Jun 2002 A1
20020084196 Liamos et al. Jul 2002 A1
20020125146 Chan et al. Sep 2002 A1
20020139692 Tokunaga et al. Oct 2002 A1
20020157967 Ling et al. Oct 2002 A1
20020180446 Kuhr et al. Dec 2002 A1
20020185375 Wogoman Dec 2002 A1
20030064525 Liess Apr 2003 A1
20030113933 Jansson et al. Jun 2003 A1
20030119208 Yoon et al. Jun 2003 A1
20030136673 Pilloud et al. Jul 2003 A1
20030146110 Karinka et al. Aug 2003 A1
20030148169 Willner et al. Aug 2003 A1
20030149348 Raskas Aug 2003 A1
20030159927 Lewis et al. Aug 2003 A1
20030175737 Schulien et al. Sep 2003 A1
20030175841 Watanabe Sep 2003 A1
20030176183 Drucker et al. Sep 2003 A1
20030178322 Bolon et al. Sep 2003 A1
20030199744 Buse et al. Oct 2003 A1
20030201194 Heller et al. Oct 2003 A1
20030205465 Feng et al. Nov 2003 A1
20030209450 McVey et al. Nov 2003 A1
20040005716 Beaty et al. Jan 2004 A9
20040007461 Edelbrock Jan 2004 A1
20040026253 Leddy et al. Feb 2004 A1
20040033165 Lewis et al. Feb 2004 A1
20040040840 Mao et al. Mar 2004 A1
20040045821 Cui et al. Mar 2004 A1
20040054267 Feldman et al. Mar 2004 A1
20040055898 Heller et al. Mar 2004 A1
20040060818 Feldmen et al. Apr 2004 A1
20040061841 Black et al. Apr 2004 A1
20040074772 Kumar et al. Apr 2004 A1
20040079653 Karinka et al. Apr 2004 A1
20040099531 Srinivasan et al. May 2004 A1
20040118682 Murray et al. Jun 2004 A1
20040149577 Kumar et al. Aug 2004 A1
20040157337 Burke et al. Aug 2004 A1
20040157338 Burke et al. Aug 2004 A1
20040157339 Burke et al. Aug 2004 A1
20040180444 Rannikko et al. Sep 2004 A1
20040224137 Rogalska et al. Nov 2004 A1
20040225230 Liamos et al. Nov 2004 A1
20040245121 Nagakawa et al. Dec 2004 A1
20040253367 Wogoman Dec 2004 A1
20040256248 Burke et al. Dec 2004 A1
20040259180 Burke et al. Dec 2004 A1
20040260511 Burke et al. Dec 2004 A1
20050009126 Andrews et al. Jan 2005 A1
20050049473 Desai et al. Mar 2005 A1
20050069892 Lyengar et al. Mar 2005 A1
20050164322 Heller et al. Jul 2005 A1
20050176153 O'hara et al. Aug 2005 A1
20050247562 Tokunaga et al. Nov 2005 A1
20060063218 Bartkowiak et al. Mar 2006 A1
20060074564 Bartkowiak et al. Apr 2006 A1
20060085137 Bartkowiak et al. Apr 2006 A1
20060191787 Wang et al. Aug 2006 A1
20070074977 Guo et al. Apr 2007 A1
20070080073 Wu et al. Apr 2007 A1
20080102441 Chen et al. May 2008 A1
20080145878 Marfurt Jun 2008 A1
20080149480 Bell Jun 2008 A1
20090014339 Beer et al. Jan 2009 A1
20090026094 Deng et al. Jan 2009 A1
20120211361 Wu Aug 2012 A1
20120298507 Wu Nov 2012 A1
20130240377 Wu Sep 2013 A1
Foreign Referenced Citations (167)
Number Date Country
2423837 Oct 2000 CA
2358993 May 2001 CA
1322299 Oct 2000 CN
1328156 Dec 2001 CN
1598564 Oct 2004 CN
229500 Jun 1985 DE
271179 Aug 1989 DE
4003194 Aug 1991 DE
4100727 Jul 1992 DE
19944318891 Dec 1994 DE
19824629 Dec 1999 DE
69915850 Jan 2005 DE
34049 Aug 1981 EP
57110 Aug 1982 EP
120715 Oct 1984 EP
121385 Oct 1984 EP
127958 Dec 1984 EP
10375 Dec 1985 EP
164180 Dec 1985 EP
255291 Feb 1986 EP
206218 Dec 1986 EP
213343 Mar 1987 EP
215678 Mar 1987 EP
230472 Aug 1987 EP
241309 Oct 1987 EP
287883 Oct 1988 EP
330517 Feb 1989 EP
354441 Feb 1990 EP
359531 Mar 1990 EP
359831 Mar 1990 EP
383322 Aug 1990 EP
417796 Mar 1991 EP
470649 Feb 1992 EP
471986 Feb 1992 EP
537761 Apr 1993 EP
546536 Jun 1993 EP
546796 Jun 1993 EP
0628810 Dec 1994 EP
636880 Feb 1995 EP
640832 Mar 1995 EP
651250 May 1995 EP
186286 Jul 1996 EP
732406 Sep 1996 EP
732590 Sep 1996 EP
0741186 Nov 1996 EP
0762112 Mar 1997 EP
800086 Oct 1997 EP
837320 Apr 1998 EP
840122 May 1998 EP
851224 Jul 1998 EP
859230 Aug 1998 EP
878708 Nov 1998 EP
878713 Nov 1998 EP
887421 Dec 1998 EP
894509 Feb 1999 EP
942278 Sep 1999 EP
964059 Dec 1999 EP
1156324 Nov 2002 EP
0 800 086 Jan 2003 EP
1279742 Jan 2003 EP
1411348 Apr 2004 EP
2184236 Jan 2003 ES
2223185 Feb 2005 ES
2325920 Sep 1976 FR
2295676 Jun 1996 GB
62209350 Sep 1987 JP
3260739 Nov 1991 JP
09089832 Apr 1997 JP
11087213 Mar 1999 JP
2120657 May 1999 JP
2003028826 Jan 2003 JP
200361650 Mar 2003 JP
200403478 Jan 2004 JP
2004093478 Mar 2004 JP
2004300328 Oct 2004 JP
2005147990 Jun 2005 JP
WO 8101794 Jul 1981 WO
WO 8203729 Oct 1982 WO
WO 8300926 Mar 1983 WO
WO 8600138 Jan 1986 WO
WO 8602732 May 1986 WO
WO 9005293 May 1990 WO
WO 9005910 May 1990 WO
WO 9201928 Feb 1992 WO
WO 9207655 May 1992 WO
WO 9215704 Sep 1992 WO
WO 9215859 Sep 1992 WO
WO 9215861 Sep 1992 WO
WO 9215950 Sep 1992 WO
WO 9219961 Nov 1992 WO
WO 9222669 Dec 1992 WO
WO 9309433 May 1993 WO
WO 9321928 Nov 1993 WO
WO 9503542 Feb 1995 WO
WO 9507050 Mar 1995 WO
WO 9513535 May 1995 WO
WO 9513536 May 1995 WO
WO 9522597 Aug 1995 WO
WO 9604398 Feb 1996 WO
WO 9607908 Mar 1996 WO
WO 9613707 May 1996 WO
WO 9615454 May 1996 WO
WO 9614026 Oct 1996 WO
WO 9633403 Oct 1996 WO
WO 9700441 Jan 1997 WO
WO 9702487 Jan 1997 WO
WO 9708544 Mar 1997 WO
WO 9716726 May 1997 WO
WO 9718465 May 1997 WO
WO 9729366 Aug 1997 WO
WO 9729847 Aug 1997 WO
WO 9730344 Aug 1997 WO
WO 9739343 Oct 1997 WO
WO 9742882 Nov 1997 WO
WO 9742888 Nov 1997 WO
WO 9745719 Dec 1997 WO
WO 9805424 Feb 1998 WO
WO 9819153 May 1998 WO
WO 9819159 May 1998 WO
WO 9829740 Jul 1998 WO
WO 9844342 Oct 1998 WO
WO 9858246 Dec 1998 WO
WO 9858250 Dec 1998 WO
WO 9922227 May 1999 WO
WO 9922230 May 1999 WO
WO 9945375 Sep 1999 WO
WO 9967628 Dec 1999 WO
WO 0016089 Mar 2000 WO
WO 0020626 Apr 2000 WO
WO 0020855 Apr 2000 WO
WO 0029540 May 2000 WO
WO 0057011 Sep 2000 WO
WO 0077523 Dec 2000 WO
WO 0103207 Jan 2001 WO
WO 0133206 May 2001 WO
WO 0133216 May 2001 WO
WO 0156771 Aug 2001 WO
WO 0157510 Aug 2001 WO
WO 0157513 Aug 2001 WO
WO 0165246 Sep 2001 WO
WO 0167099 Sep 2001 WO
WO 0201214 Jan 2002 WO
WO 0231482 Apr 2002 WO
WO 02031481 Oct 2002 WO
WO 02077633 Oct 2002 WO
WO 03001195 Jan 2003 WO
WO 03069304 Feb 2003 WO
WO 03066554 Jun 2003 WO
WO 03087802 Oct 2003 WO
WO 2004023128 Mar 2004 WO
WO 2004040286 May 2004 WO
WO 2004046707 Jun 2004 WO
WO 2004053476 Jun 2004 WO
WO 2004062801 Jul 2004 WO
WO 2004113896 Dec 2004 WO
WO 2004113912 Dec 2004 WO
WO 2004113913 Dec 2004 WO
WO 2005001462 Jan 2005 WO
WO 2005001463 Jan 2005 WO
WO 2005003748 Jan 2005 WO
WO 2005008231 Jan 2005 WO
WO 2005022143 Mar 2005 WO
WO 2005040407 May 2005 WO
WO 2005045234 May 2005 WO
WO 2005078118 Aug 2005 WO
WO 2006079797 Aug 2006 WO
WO 2006110504 Oct 2006 WO
Non-Patent Literature Citations (5)
Entry
Dalrymple-Alford, P., et al., “Peak Shapes in Semi-differential Electroanalysis”, “Anal. Chem.”, 1977, pp. 1390-1394, vol. 49, No. 9, Publisher: American Chemical Society , Published in: USA.
Hall, J.W. et al., “Automated Determination of Glucose using ENZ Glucose Oxidase and Potassium Ferrocyanide ENZ Peroxidase,” Analytical Biochemistry, vol. 26, No. 1, 1968, pp. 12-17.
PCT International Search Report dated Jun. 2, 2005, PCT/US2005/003622, 3 pages.
Yao, et al., “A Thin-Film Glucose Electrode System with Compensation for Drifit”, 1989, pp. 742-744, vol. XXXV.
Yao, et al., “The Low-Potential Approach of Glucose Sensing”, 1986, pp. 139-146, vol. BME-33, No. 2.
Related Publications (1)
Number Date Country
20140174951 A1 Jun 2014 US
Provisional Applications (1)
Number Date Country
60542362 Feb 2004 US
Divisions (1)
Number Date Country
Parent 10590765 US
Child 14193214 US